3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 1
4
Phase 3
2
Phase 1/2
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Classical hematology
1
Conditions
Leukemia, Myeloid, Acute
2
Pathologic Complete Response
1
Lymphoma, T-Cell
1
Lymphoma
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
Cytarabine
89
Daunorubicin
45
Azacitidine
43
Idarubicin
27
venetoclax
26
fludarabine
26
Etoposide
25
Cyclophosphamide
25
Mitoxantrone
22
Decitabine
19
Busulfan
19
Methotrexate
16
Gemtuzumab
14
Granulocyte Colony-Stimulating Factor
12
Whole-Body Irradiation
10
Peripheral Blood Stem Cell Transplantation
10
Melphalan
10
gilteritinib
9
Filgrastim
9
fludarabine phosphate
8
Tacrolimus
8
Mycophenolic Acid
8
Cyclosporine
8
Tretinoin
7
Radiotherapy
7
Drug Therapy
7
Observation
6
Homoharringtonine
6
Antilymphocyte Serum
6
quizartinib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Leukemia, Myeloid, Acute
×
cc-486
×
Clear all
NCT01757535
2025-07-08
QUAZAR AML-001
Celgene
Phase 3
Completed
472 enrolled
24 charts
1 FDA
NCT04173533
2024-05-14
AMADEUS
University of Birmingham
Phase 3
Unknown
326 enrolled